Peer Review History
| Original SubmissionJuly 20, 2019 |
|---|
|
PONE-D-19-19703 A two-step procedure to generate utilities for the Infant health-related Quality of life Instrument (IQI) PLOS ONE Dear Mr. Krabbe, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Dec 13 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Jing Tian Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following in the Financial Disclosure section: 'This study has been funded by Nestec Ltd to finance the research activities of RJ, KV, AvA and PK. PD and LD are employed at Nestlé Research Center. The funder provided support in the form of salaries for authors [RJ, KV, PD, LD, AvA, PK], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.' We note that one or more of the authors are employed by a commercial company: Nestle 1. Please provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include an updated Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests 3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The purpose of this study is to generate an algorithm to estimate utilities for the infant quality of life instrument (IQI) using a two-step choice-based modelling approach. The approach and methods used for the study seem appropriate and I have just a few comments. This study uses a population from the UK, USA and China-Hongkong and my question relates to why this population was used. Was it based on availability or was it to ensure generalisability? In addition, I am not entirely sure why the second study was limited to USA. Perhaps the authors need to comment on the generalisability of the results. It would help if a table with the utility values for the various health states is presented in the appendix. Linked to this point, the lowest/worst health state is represented by 0.015 and as a result, there is a gap between this value and zero which is usually considered the anchor point for utility scales. As a result of this, the use of the IQI would imply that there could potentially be an over-estimation of utility for the severest health states which could potentially lead to a situation where the paediatric population would be disadvantaged compared to e.g. an adult population. Perhaps, the authors should also comment on the implications of using this instrument to assess the cost-effectiveness of interventions. Reviewer #2: General comments to the authors Thank you to the authors for providing me with the opportunity to review this novel and interesting quality of life research paper. The authors identified a substantial gap in the literature in their previous published work and are now developing the algorithm for the previously established descriptive system of the IQI to capture and assess proxy-reported outcomes for the derivation of health state utility valuations for infants aged 0-1 years. I note that the underpinning theory regarding the development of the IQI’s descriptive/classification system by Krabbe et al’s authorship team in 2018 (https://doi.org/10.1371/journal.pone.0203276) where the views of the primary caregivers serve as the proxy and provide the response. This paper is the logical next step to that published work. Overall, I consider that it would be useful to provide some additional background in the Introduction section of the manuscript regarding the development of the IQI’s descriptive/classification system, including the literature search and use of expert panels in this development. This would contextualise the reasons for this paper to the broader readership. I also suggest that the Discussion section could be more circumspect about the development of this initial (albeit important) value set. Please include caveats regarding future confirmatory and clinical studies and perhaps refinement of the value set over time. Finally, I also suggest that the manuscript should be thoroughly checked for grammatical errors. I recommend the paper for publication if my key concerns are appropriately addressed as outlined below. Specific comments to the authors: Introduction section: Line 69: The introductory paragraph could perhaps mention full health economic evaluation and cost-utility analyses to contextualise the generation of utilities as a health economic input metric for cost-utility analyses (refer Drummond et al 2015). Line 86: As noted in the general comments, please include some additional background regarding the development of the IQI’s descriptive system. Line 93 Aims: The ‘aims’ paragraph could be improved by describing how you planned to achieve your key objective with some further detail and perhaps numbered sequentially. Methods section: Line 108: please provide further explanation regarding the ‘skin’ dimension being classified ‘qualitatively’. Is the ‘mood’ dimension perhaps phrased qualitatively too? Do you mean that there needs to be a more subjective assessment of the response? Line 110: is the term ‘parents’ = primary carers? Are there ‘primary carers’ of the infants who are not classified as parents? Please clarify. Line 219: Could you please relabel this “Recruitment of Participants (or Respondents)”. Please expand on this fundamental section: the recruitment strategy requires additional explanation . I note that a fulsome explanation was provided of the discrete choice design and the subsequent analyses. It is insufficient to say that participants were reached through a market research company. I need to understand the sampling and any bias. I also need to understand why participants from the USA were recruited only for the second study. Please also clarify in this section the meaning of the ‘main study’ and the ‘additional study’. Results section: I note that the line numbers on the PDF files were not reproduced from the Results section, therefore the below comments are outlined section by section. Given the international nature of the cohort, stratified results should be reported beyond section 3.1 to highlight any cultural/country differences. Section 3.4: Please provide further contextualisation regarding the utility derived for ‘1111112’ and ‘1111111’. The reference point and the derivation of a utility score of 1.0 for 1111112 and 0.96 for 1111111 may require further clarification for the broader readership. Discussion section: The Discussion is perhaps the weakest section of the paper and should be expanded to showcase the key and secondary findings of the paper, thoroughly outline all of the limitations of the study, and provide a robust conclusion. The first paragraph should provide an overall summary of the findings. One sentence is inadequate and this sentence describes what was done rather than a succinct summary of the key findings of the paper. The Discussion also does not outline the international nature of the cohort, nor issues surrounding cultural differences for the proxy-respondents as primary carers of infants and therefore the generaton of potentially different value sets? In the second paragraph of the Discussion, perhaps remove the word ‘first’ – the authors do not then go to ‘second’, ‘third’ etc to expand on the key findings. The second paragraph could also reference the AQoL-8D multi-attribute utility instrument’s algorithmic range as an example of an instrument that does not record a utility value that is less than zero. In the third paragraph, I would remove the statement that “It is likely that states worse than death are less self-evident than generally thought and that the lowest utility for the EQ-5D-3L may have been an accidental finding”. Perhaps the suggestion could be underpinned by statements about the instruments only 243 health states and that the instrument is relatively insensitive to complex and chronic disease states. Please use appropriate referencing for this statement. The fourth paragraph could be tightened to provide some additional explanation and contextualisation regarding the underpinning model and the advantages of the model. This paragraph in its current form is somewhat jumbled. Limitations section. Please be more circumspect in this section – one limitation only is outlined. The recruitment/sampling strategy is not properly described therefore I can not comment on limitations regarding the sampling strategy. Similarly, stratified results are not presented I would expect that cultural differences would be evident in stratified results. Stratified results could also be the subject of further discussion. The conclusion should provide additional explanation regarding future research and confirmatory studies. Reviewer #3: The sample consisted of members of the general population (n=1409) and infant caregivers (n=1229). Were the members of the general population parents? If not, is there reason to believe that the sample of the general population would answer the questions significantly differently than the infant caregivers? I’m assuming from some of the information that follows in the manuscript, that yes, the subsamples answer some questions differently, but In section 3.2 “states worse than death”, the authors write, “Among the health states in the main study, the one most frequently mentioned as being worse than death was 4241241 (2.2%) for the general population and 4244231 (2.4%) for the primary caregivers.” The digits are poorly explained in section 2.1 instrument. A slightly more detailed explanation would be useful for the reader earlier in the paper (perhaps expand the example given in line 113, “e.g., 3231421 equates to moderately affected sleep, slight feeding problems, moderate breathing problems, sleeps well, inconsolable crying, dry or red skin, highly playful/highly interactive.” Because as it is, I’m not even certain that I have interpreted this correctly. Is this correct? Figure 2 is confusing because at the top it says, “Suppose that an infant’s first year of life is spent mainly in either State A or State B and that its health is uncertain afterwards.” At the bottom of the figure, “Please indicate if you would consider health state A and B as better or worse than death.” The use of the word “and” at the bottom leads me to believe that the infant has all the conditions in both A and B. Is this because there are 2 options to answer at the bottom? “The main limitation associated with this study is that no obvious state worse than death was found.” It seems that the descriptions “Severely disturbed sleep, severe feeding problems, severe breathing problems, severe stool problems, inconsolable crying, bleeding or cracked skin, low-energy/inactive/dull” do not describe the pain of the infant and so do not elicit a response from an adult that there is no obvious state worse than death. Is it possible that the adults who took this survey view the 4’s as problems that occur occasionally and do not see these issues as worse than death? Adults can forget that infants are altricial, making the 4’s much more severe than they are for adults. How do you expect the results would vary if you included an outcome statement after each option (e.g., “severe stool/poo problems, resulting in hospitalization”? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: Yes: Julie Campbell [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
A two-step procedure to generate utilities for the Infant health-related Quality of life Instrument (IQI) PONE-D-19-19703R1 Dear Dr. Krabbe, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Jing Tian Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: Dear authors, thank you for responding to all of my comments and suggestions in a thorough and robust manner. I now recommend the article for publication. Good luck with your publication and future endeavours with this interesting work. With kindest regards. Reviewer #3: The authors were careful to respond to all my inquiries and addressed them in the manuscript when necessary for clarification. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: Yes: Dr Julie A. Campbell Reviewer #3: Yes: Julie Campbell |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .